My first thought was that the motivation to combine drugs with one another is not always scientific and that PFE is combining already approved drugs they have or can use under an agreement. Then, I thought they use sunitinib to provide a short-term effect, in which antiangiogenesis halts the tumor growth as it takes time for the immune system to kick in and provide a long-term effect. After reading the paper below, I think I can see the scientific rationale behind that combination therapy: sunitinib downregulates myeloid-derived suppressor cells and tremelimumab activates T cells so together they might provide a synergistic effect to the vax. Kind of an educated fishing expedition :)
News 
Market Data 
Discover 
